Bristol Myers' Opdivo Combo Meets Endpoint Goal In Lung Cancer Trial

  • Bristol Myers Squibb & Co BMY has announced topline data from Phase 3 CheckMate -816 trial in patients with resectable stage IB to IIIA non-small cell lung cancer (NSCLC). 
  • The trial evaluated Opdivo (nivolumab) plus chemotherapy compared to chemotherapy alone as neoadjuvant treatment.
  • The study met the primary endpoint of improved event-free survival (EFS). Opdivo/Chemo combo showed a statistically significant and clinically meaningful improvement in EFS compared to chemotherapy alone.
  • This combination previously showed a significant improvement of pathologic complete response (pCR), the trial's other primary endpoint.
  • The Company will complete a full evaluation of the available CheckMate -816 data and share the results at an upcoming medical conference.
  • Price Action: BMY shares are up 0.60% at $59.80 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsNon-Small Cell Lung CancerPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!